Prognostic and Predictive Biomarkers in Ovarian Cancers
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 350
- Registration Number
- NCT03010124
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 36
- Registration Number
- NCT02997332
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Feasibility of Breast Cancer Risk Evaluation in Women From the General Population
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 600
- Registration Number
- NCT02997384
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 150
- Registration Number
- NCT02997358
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 60
- Registration Number
- NCT02994576
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷Centre Hospitalier de Chauny, Chauny, France
🇫🇷Centre Marie Lannelongue, Le Plessis Robinson, France
Axillary Reverse Mapping Using Near-infrared Imaging in Invasive Breast Cancer: Predictors of Nodal Positivity
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 120
- Registration Number
- NCT02994225
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 138
- Registration Number
- NCT02992912
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 185
- Registration Number
- NCT02902874
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 90
- Registration Number
- NCT02857569
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Trial Of Pembrolizumab And Nintedanib
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 221
- Registration Number
- NCT02856425
- Locations
- 🇫🇷
Hôpital Bichat, Paris, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷IUCT--O, Toulouse, France
© Copyright 2024. All Rights Reserved by MedPath